- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.09. | Scholar Rock SMA drug rejected by FDA over manufacturing concerns | ||
| 23.09. | FDA clears under-the-skin Keytruda; MBX shares double on study data | ||
| 23.09. | Why Xoma, a drug royalty firm, is hunting biotech 'zombies' | ||
| 22.09. | MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug | ||
| 22.09. | Pfizer buys back into obesity drug chase with $4.9B Metsera deal | ||
| 22.09. | FDA clears first Barth syndrome drug amid scrutiny of rare disease stance | ||
| 22.09. | Setting cell and gene therapies up for success with a smarter CMC strategy | ||
| 22.09. | Meet the new EmVenio - where science meets people | ||
| 19.09. | CDC panel, recast by RFK Jr., softens COVID vaccine recommendations | ||
| 19.09. | Arvinas reboots, cuts more staff; Porges joins Lazard | ||
| 19.09. | CDC advisers postpone vote to delay some newborns' hepatitis B shot | ||
| 18.09. | CDC panel recommends splitting measles, varicella shots | ||
| 18.09. | A new biotech venture firm emerges, led by Bob Langer's son | ||
| 18.09. | Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs | ||
| 18.09. | Roche dives into MASH with $2.4B deal for 89bio | ||
| 17.09. | Fired CDC director says RFK Jr. aims to change childhood vaccine schedule | ||
| 17.09. | Roivant pill succeeds in rare inflammatory disease trial | ||
| 17.09. | GSK ups US investment with $30B spending plan | ||
| 17.09. | Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD | ||
| 17.09. | Ollin debuts with $100M and plans to challenge top-selling eye drugs | ||
| 16.09. | CSL nabs option to acquire a startup and its blood-clotting drug | ||
| 16.09. | Former CinCor execs reunite to helm new biotech startup | ||
| 15.09. | ATyr shares plunge on trial miss in inflammatory lung disease | ||
| 15.09. | A key CDC panel meets this week to discuss vaccines. Here's what to know. | ||
| 15.09. | Novartis dives deeper into protein degraders with second Monte Rosa deal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .